Endocyte Inc. (Nasdaq: ECYT) will narrow the development program for EC1169 and stop enrollment in the EC1456 trial sending the stock price tumbling 82 cents to close at $1.91.
Endocyte modifies clinical trials
June 02, 2017 at 20:34 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.